DGAP-Adhoc

WILEX AG: WILEX signs antibody license agreement with Telix Pharmaceuticals Limited - Seite 3

http://www.wilex.com/.

Contact	IR/PR-­support
WILEX AG	MC Services AG
Sylvia Wimmer	Katja Arnold (CIRO)
Corporate Communications	Managing Director & Partner
Tel.: [phone]	Tel.: [phone]
Email: investors[at]wilex.com	Mobile: [phone]
Grillparzerstr. 18, 81675 Munich	Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of forwardlooking
terminology such as "estimates", "believes", "expects", "may",
"will" "should" "future", "potential" or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

---

16-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language:	English
Company:	WILEX AG
	Grillparzerstr. 18
	81675 München
	Germany
Phone:	[phone] - 0
Fax:	[phone] - 99
E-mail:	[e-mail]
Internet:	www.wilex.com
ISIN:	DE000A11QVV0
WKN:	A11QVV
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

End of Announcement	DGAP News Service

536523  16-Jan-2017 CET/CEST